+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Somatostatin"

From
From
Neuroendocrine Tumors Market - Product Thumbnail Image

Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Gastric Neuroendocrine Tumors Market - Product Thumbnail Image

Gastric Neuroendocrine Tumors Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Acromegaly Treatment Market Report and Forecast 2023-2031 - Product Thumbnail Image

Acromegaly Treatment Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 160 Pages
  • Global
From
Acromegaly - Pipeline Review, H2 2020 - Product Thumbnail Image

Acromegaly - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 96 Pages
  • Global
From
From
From
From
Market Spotlight: Neuroendocrine tumors (NET) - Product Thumbnail Image

Market Spotlight: Neuroendocrine tumors (NET)

  • Report
  • May 2021
  • 42 Pages
  • Global
From
From
From
Loading Indicator

Somatostatin is a peptide hormone that is used in the treatment of various types of cancer. It is used to inhibit the release of growth hormones, which can help reduce the size of tumors. It is also used to reduce the side effects of chemotherapy and radiation therapy. Somatostatin is available in both injectable and oral forms. It is often used in combination with other drugs to treat cancer. Somatostatin is used to treat a variety of cancers, including pancreatic, prostate, and neuroendocrine tumors. It is also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin is also used to treat Cushing's syndrome, a condition caused by excessive cortisol production. Some companies that produce somatostatin include Novartis, Merck, and Pfizer. Other companies that produce somatostatin-based drugs include Ipsen, Teva, and Sandoz. Show Less Read more